Biotech

Pharma M&A avalanche deepens into double-digit billions

Strategic acquirers are writing checks at historic scale, compressing the gap between clinical-stage and commercial value. GSK acquired Nuvalent for $10.6B at a 40% premium, Eli Lilly bought Kelonia Therapeutics for up to $7B and Curevo Vaccine for up to $1.5B, J&J absorbed Sail Biomedicines for $785M, UCB outbid a reverse-merger deal to acquire Candid Therapeutics after the company had raised $370M, and Chiesi Group paid $1.9B for KalVista Pharmaceuticals. Curium's proposed $7–8B acquisition of Lantheus — a radiopharmaceutical leader serving over 14 million patients annually — signals that even capital-intensive imaging and radioligand therapy platforms are now take-out targets. Biopharma exit value reached a record $34.4B in Q2 2026, driven by this pharma M&A surge.

The public market appetite for biotech remains robust, with multiple high-profile IPOs clearing in quick succession. Kailera Therapeutics, backed by Bain Capital and focused on obesity drugs, raised a $625M IPO; Odyssey Therapeutics raised $304M on Nasdaq for its oral autoimmune small-molecule franchise; Avalyn Pharma raised $300M at an $813M valuation for inhaled antifibrotic therapies; Hemab Therapeutics raised $301.5M backed by Novo Holdings and RA Capital; and Latigo Biotherapeutics sought up to $288M. The Qatar Investment Authority participated in a $346M IPO, signaling sovereign wealth appetite. Kardigan, a cardiovascular drug developer that raised $550M+ pre-IPO, is also filing for a $100M IPO.

Why it matters · A durable IPO window with sovereign and crossover investor participation validates the public market as a viable exit path, encouraging later-stage private rounds and raising the stakes for pre-IPO Series C/D investors.

Chai Discovery has emerged as the highest-signal AI-biology company of the cycle, recruiting co-founders from OpenAI and Stripe, senior researchers from David Baker's lab and Pfizer/Genentech, and engineers from Stripe — an unusual cross-disciplinary pedigree. The company's Chai-1 foundation model for molecule engineering is being positioned as computer-aided design infrastructure for the industry, a direct contrast to Isomorphic Labs (DeepMind spin-out run by Demis Hassabis), which is developing drugs directly. Eli Lilly is cited as structurally incentivized to adopt AI rapidly to sustain its trillion-dollar valuation through continuous blockbuster drug production. RA Capital Management, one of the theme's most active investors with 7 deals, participated alongside Bill Gates and Jeff Bezos in a $263M Series D/E round — reflecting crossover investor conviction in long-cycle AI-biology bets.

Why it matters · Companies that own foundational biology AI infrastructure — rather than single drug programs — are positioning for winner-take-most network effects, making early stakes in platforms like Chai Discovery and Isomorphic Labs disproportionately valuable.

Series B accounts for 25 deals totaling $11.1B in the last 90 days — the single largest capital layer by both deal count and dollar volume, dwarfing Series C ($3.1B) and Series D+ ($1.6B) combined. The $3.05B Series B and a $263M Series D/E round illustrate how mid-stage rounds are absorbing institutional capital from crossover investors, including RA Capital Management and GV, that previously waited for pre-IPO stages. Large biotech rounds are explicitly cited as a signal of continued LP appetite for long-cycle science bets running parallel to the AI wave.

Why it matters · Founders and early-stage investors benefit from a compressed Series A-to-B timeline as crossover capital floods mid-stage, but it also means Series B valuations are at risk of being stretched if the IPO window narrows.

Curium's proposed $7–8B acquisition of Lantheus — which commercializes PYLARIFY® for prostate cancer PET imaging and is expanding into radioligand therapies — signals that radiopharmaceuticals have graduated from niche diagnostic infrastructure to a strategic asset class. Lantheus serves clinicians across oncology, cardiology, and neurology, and its AI-powered imaging tools add a software moat to the radiopharmaceutical platform. The deal size, discussed across multiple signals over several days, reflects how targeted radioligand therapy pipelines are now commanding premium M&A multiples.

Why it matters · Investors holding radiopharmaceutical or radioligand therapy assets should expect strategic acquirer interest at significant premiums as big pharma races to build end-to-end precision oncology platforms.